Tigecycline is an antibiotic that is used to treat a variety of bacterial infections. According to the drug patent watch website, the tradename for tigecycline is Tygacil, and it is used to treat complicated skin and skin structure infections, complicated intra-abdominal infections, and community-acquired bacterial pneumonia [1].

The Infectious Diseases Society of America (IDSA) provides guidance on the use of tigecycline in the treatment of drug-resistant infections. The IDSA recommends tigecycline as a potential treatment option for drug-resistant infections, including those caused by carbapenem-resistant Enterobacteriaceae (CRE) [2]. However, the IDSA notes that tigecycline has limited activity against some gram-negative bacteria and should be used in combination with other antibiotics when treating CRE infections [2].

A study published in the journal Antimicrobial Agents and Chemotherapy found that tigecycline has activity against a range of drug-resistant bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE) [3]. The study also found that tigecycline has activity against Acinetobacter baumannii, a gram-negative bacterium that is often resistant to multiple antibiotics [3]. However, the study noted that tigecycline has limited activity against Pseudomonas aeruginosa, another gram-negative bacterium that is often resistant to multiple antibiotics [3].

In summary, tigecycline is a valuable antibiotic for the treatment of drug-resistant infections, including those caused by MRSA, VRE, and CRE. However, tigecycline has limited activity against some gram-negative bacteria, such as Pseudomonas aeruginosa, and should be used in combination with other antibiotics when treating CRE infections.

Sources:

[1] <https://www.drugpatentwatch.com/p/tradename/TIGECYCLINE>
[2] <https://www.idsociety.org/practice-guideline/amr-guidance/>
[3] <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960994/>